Drug lookup
Drug reference

miglitol

α-Glucosidase inhibitor · Antidiabetic agent

α-Glucosidase inhibitorAntidiabetic agent
CDSCO approved
EXCRETION
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
not curated
Top interactionssee all 2
  • GatifloxacinSevereDatabaseDDInter

Mechanism

Miglitol reduces the intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α-glucosidase in the intestinal brush border. This slows down carbohydrate digestion and absorption, reducing postprandial glucose excursions.

Indications

Adjunct to diet and exercise in type 2 diabetesUsed in combination with other oral antidiabetic agents or insulintype 2 diabetes mellitus

Dosing

Adult
25–100 mg three times daily (at the beginning of each meal)

Pharmacokinetics

Bioavailability
Substantial, but variable absorption
Metabolism
Not specified
Excretion
Almost entirely by the kidney

Side effects

Common
MalabsorptionFlatulenceDiarrheaAbdominal bloating
Serious
  • Cutaneous hypersensitivity (rare)

Drug interactions

Gatifloxacin
Severe
Database

Clinical effect not specified

Source: DDInter

Pancreatin
Moderate
Database

Reduced efficacy of miglitol in controlling postprandial glucose levels.

Monitor blood glucose levels closely. If concurrent use is necessary, consider adjusting the dose of miglitol or pancreatin, or administering them at different times. The clinical significance is generally considered low unless very high doses of pancreatin are used.

10 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.

Related guidelines

Ask House about miglitol

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team